The medical management of refractory Overactive Bladder

被引：10

作者：

Robinson, Dudley ^{[1
]}

Giarenis, Ilias ^{[1
]}

Cardozo, Linda ^{[1
]}

机构：

[1] Kings Coll Hosp London, Dept Urogynaecol, London, England

来源：

MATURITAS | 2013年 / 74卷 / 04期

关键词：

Management; Refractory; Overactive Bladder; Antimuscarinics; TOLTERODINE EXTENDED-RELEASE; DOUBLE-BLIND; POSTMENOPAUSAL WOMEN; EFFICACY; OXYBUTYNIN; PLACEBO; TOLERABILITY; SOLIFENACIN; FESOTERODINE; MIRABEGRON;

D O I：

10.1016/j.maturitas.2013.01.012

中图分类号：

R592 [老年病学]; C [社会科学总论];

学科分类号：

03 ; 0303 ; 100203 ;

摘要：

Overactive Bladder (OAB) is a clinical syndrome describing the symptom complex of urgency, with or without urgency incontinence and is usually associated with frequency and nocturia. Those women with refractory or intractable symptoms following initial conservative and antimuscarinic medication may benefit from further assessment and investigation of their symptoms prior to considering different approaches to drug therapy. This review is the first of two to cover the management of intractable OAB in women and provides a practical clinical approach to managing women with refractory OAB symptoms. This paper covers the investigation and medical management of this demanding patient group whilst the second paper will focus on the role of more invasive treatments such as Botulinum Toxin, neuromodulation and reconstructive surgery. (C) 2013 Elsevier Ireland Ltd. All rights reserved.

引用

页码：386 / 390

页数：5

共 29 条

[1] Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults [J].

Alhasso, A. A. ;

McKinlay, J. ;

Patrick, K. ;

Stewart, L. .

COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2006, (04)

[2]

Andersson KE., 2009, INCONTINENCE 4 INT C, P631

[3]

Cardozo L, 2010, BJU INT, V106, P506, DOI 10.1111/j.1464-410X.2009.09160.x

[4]

Chapple CR, 2008, EUR UROL SUPPL, V7, P239

[5] The effects of antimuscarinic treatments in overactive bladder: An update of a systematic review and meta-analysis [J].

Chapple, Christopher R. ;

Khullar, Vik ;

Gabriel, Zahava ;

Muston, Dominic ;

Bitoun, Caty Ebel ;

Weinstein, David .

EUROPEAN UROLOGY, 2008, 54 (03) :543-562

[6] Effect of an ATP-sensitive potassium channel opener in subjects with overactive bladder: A randomized, double-blind, placebo-controlled study (ZD0947IL/0004) [J].

Chapple, CR ;

Patroneva, A ;

Raines, SR .

EUROPEAN UROLOGY, 2006, 49 (05) :879-886

[7] A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: Results of the STAR trial [J].

Chapple, CR ;

Martinez-Garcia, R ;

Selvaggi, L ;

Toozs-Hobson, P ;

Warnack, W ;

Drogendijk, T ;

Wright, DM ;

Bolodeoku, J .

EUROPEAN UROLOGY, 2005, 48 (03) :464-470

[8] Overactive bladder treatments in early phase clinical trials [J].

Colli, Enrico ;

Digesu, Giuseppe Alessandro ;

Olivieri, Lorenza .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (07) :999-1007

[9] Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: Results of the OPERA trial [J].

Diokno, AC ;

Appell, RA ;

Sand, PK ;

Dmochowski, RR ;

Gburek, BM ;

Klimberg, IW ;

Kell, SH .

MAYO CLINIC PROCEEDINGS, 2003, 78 (06) :687-695

[10] Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence [J].

Dmochowski, RR ;

Sand, PK ;

Zinner, NR ;

Gittelman, MC ;

Davila, GW ;

Sanders, SW .

UROLOGY, 2003, 62 (02) :237-242

← 1 2 3 →